Labcorp 2025-26: Diagnostics +5.5%, FY26 EPS $17.65-$18.25, Invitae Integrated
FY25 revenue $13.95B (+7%); op income $1.52B (+40%); NI $877M (+18%); EPS $10.46 (+18%). Q4 Diagnostics Laboratories revenue $2.7B (+5.5%) — organic +4.1%, acquisitions +1.5%; volume +2.2% / price-mix +3.3%. Q4 Biopharma Laboratory Services revenue $793M (+3.4%) — organic +0.6%, FX +2.8%. Central Labs Q4 +11% (+8% cc). 130+ new specialty tests launched FY25. Invitae integration completed. Labcorp OnDemand growing in Consumer Health. AI-powered solutions advancing. New central laboratory facility investment announced. FY26 guide: enterprise revenue +4.7-6%; Diagnostics +5-6%; BLS +3-5%; adj EPS $17.65-$18.25 (+9% midpoint); FCF $1.24-$1.36B.
Key takeaways
- Q4 Diagnostics +5.5% YoY (organic +4.1%) — strong organic momentum. Volume +2.2% (organic + acquisitions each contributing 1.1%) + Price/mix +3.3%. The price/mix expansion (organic +3.0% / acquisition +0.3%) is driven by tests-per-session increase — i.e., more diagnostic tests per patient encounter. The unit economic improvement reflects specialty testing scale.
- 130+ new specialty tests launched in 2025. Specialty testing is the structural margin lever — higher-priced, less-commoditized tests with better gross margins than commodity routine work. The 130-test launch cadence is exceptional and validates the multi-year specialty strategy.
- Invitae integration completed in FY25. The 2024 acquisition is now fully operational. Invitae brings genetic testing + reproductive health + oncology / hereditary cancer diagnostics. The integration boosts specialty mix and per-test pricing.
- FY26 enterprise revenue +4.7-6% / adj EPS $17.65-$18.25 (+9% midpoint). Diagnostics +5-6% (majority organic) + BLS +3-5% with FX/early-development drag = combined 4.7-6%. Both segments expected to improve margins. The $17.65-$18.25 EPS is +9% from $16.21 FY25 base (mgmt-disclosed adj EPS).
- Strategic investment in new central laboratory facility announced. Multi-year capacity build supporting specialty + BLS growth + tech / AI rollout. Capex investment now → revenue + margin in FY27-FY30.
Business
Labcorp Holdings, Inc. is one of the two largest US clinical laboratory diagnostics companies + global biopharma laboratory services provider. Two reportable segments + AI / specialty / Consumer Health expansion:
- Diagnostics Laboratories (~80% of revenue). Routine + specialty clinical testing for hospitals, health systems, physicians, pharmacy chains, consumer + employer customers. Q4 revenue $2.7B (+5.5% YoY) — volume +2.2% / price-mix +3.3%. The structural compounder. Includes Labcorp OnDemand (Consumer Health DTC).
- Biopharma Laboratory Services (BLS) (~20% of revenue). Drug development services — clinical pharmacology, central labs, biomarker, companion diagnostics. Q4 revenue $793M (+3.4% YoY) — organic +0.6%, FX +2.8%. Central Labs Q4 +11% (+8% cc) standout. Early Development Services facing actions / streamlining.
Strategic moves FY25:
- Deepening partnerships with health systems and hospital labs
- 130+ new specialty tests launched in 2025
- Invitae integration completed (genetic testing + reproductive health + oncology)
- Labcorp OnDemand growing (Consumer Health DTC)
- Technology + AI-powered solutions progressing
- Strategic investment in new central laboratory facility announced
- Continued diagnostic acquisitions
- Multi-year capacity build
- $-450M FY25 buyback (vs $-250M FY24, +80%)
- Dividend $-241M (-1% YoY)
FY25 financial performance
| Metric (FY) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue ($B) | 11.86 | 12.16 | 13.01 | 13.95 |
| Revenue YoY | n/a | +3% | +7% | +7% |
| Op income ($B) | 1.44 | 0.73 | 1.09 | 1.52 |
| Op margin | 12.1% | 6.0% | 8.4% | 10.9% |
| Net income ($B) | 1.28 | 0.42 | 0.75 | 0.88 |
| Diluted EPS ($) | 13.96 | 4.77 | 8.84 | 10.46 |
| FCF ($B) | 1.47 | 0.87 | 1.10 | 1.21 |
| Capex ($M) | -482 | -454 | -490 | -435 |
| Total debt ($B) | 6.25 | 5.95 | 7.27 | 7.20 |
| Dividends ($M) | -195 | -254 | -243 | -241 |
| Buyback ($B) | -1.15 | -1.04 | -0.25 | -0.45 |
The earnings progression: revenue +7% FY25 (consistent with FY24); op income +40% YoY (from $1.09B → $1.52B) reflects margin recovery + Invitae integration synergies + specialty mix expansion. Op margin 10.9% (+250bp YoY) — meaningful structural improvement. EPS $10.46 (+18%) — operating leverage at scale.
FCF $1.21B (+10%) reflects continued cash generation. Total debt $7.20B (basically flat YoY).
Capital allocation
- Capex $-435M FY25 (-11% YoY). FY26 with new central lab facility investment will see step up.
- Dividends $-241M FY25 (-1% YoY). Steady payout.
- Buybacks $-450M FY25 (+80% vs $-250M FY24). Capital return acceleration.
- M&A Invitae integrated; selective tuck-ins continuing.
- Debt $7.20B (basically flat).
- FCF $1.21B (+10%).
FY26 outlook (per Q4 2025 call, 2026-02-17)
| FY26 framework | Detail |
|---|---|
| Enterprise revenue growth | +4.7% to +6% |
| Diagnostics revenue growth | +5% to +6% (majority organic) |
| BLS revenue growth | +3% to +5% (FX + early development drag) |
| Enterprise adj EPS | $17.65 to $18.25 |
| Adj EPS midpoint growth | ~9% |
| FCF | $1.24B to $1.36B |
| Margin trajectory | Both segments improving |
The +9% midpoint EPS growth on +5% revenue + meaningful margin expansion = high-quality compounding trajectory. Diagnostics organic +5-6% led by specialty mix + AI integration; BLS +3-5% reflects FX + early development streamlining offset by Central Labs growth.
Key risks
PAMA (Protecting Access to Medicare Act). Q4 mgmt explicit risk. PAMA reimbursement cuts have been delayed multiple times; the next delay decision matters for routine testing pricing. If PAMA cuts proceed, Diagnostics revenue + margin compress meaningfully.
Competitive landscape in diagnostics. Quest Diagnostics (DGX) is the dominant competitor; smaller players + reference labs + hospital labs all compete. Price competition + customer churn / win rates in commercial + Medicare Advantage matter.
Timing of M&A and business streamlining in early development. Q4 mgmt called out — early development streamlining + actions create timing risk in BLS revenue + margin. Multi-quarter execution required.
Invitae integration tail risk. Integration completed but synergy delivery + customer retention require continued execution. Genetic testing market dynamics + reimbursement policy + competitive intensity all matter.
Specialty test pricing. 130+ new tests launched FY25 — specialty test pricing depends on payer coverage + competitive dynamics + clinical evidence. New test launches require multi-year reimbursement cycles.
Hospital + health system partnerships. Large customers (hospitals, health systems) drive significant revenue. Customer concentration matters; renewal cycles + competitive pressures affect economics.
FX volatility. BLS Q4 FX +2.8% reflects EUR + GBP + JPY translation. FY26 FX assumptions affect reported BLS growth.
Capital deployment + new central lab investment. Multi-year capacity build creates near-term capex headwind. Returns depend on volume + utilization + AI integration delivering productivity.
AI commoditization in laboratory services. AI-powered solutions advancing — but AI is broadly available. Labcorp's differentiation depends on data + clinical workflow + customer intimacy + execution.
Reimbursement policy / Medicare Advantage. US lab reimbursement environment evolving — Medicare PFS + commercial payer pricing + Medicare Advantage policies all affect economics.
Test mix shift / consumer DTC. Labcorp OnDemand (Consumer Health DTC) growing but margins different from B2B. Mix shift impacts overall margin trajectory.
Macroeconomic + utilization. US healthcare utilization affects test volume. Recession or utilization pressure could compress diagnostic volume.
Goodwill / intangibles. Heavy M&A creates large goodwill + intangible balance — impairment risk if business performance disappoints.
Bottom line
Labcorp FY25 is the structural compounding + Invitae-integrated year: revenue +7%, op income +40%, EPS +18%, op margin +250bp to 10.9%, FCF +10% to $1.21B. Q4 Diagnostics +5.5% with organic +4.1% — strong volume + price-mix dynamics. 130+ new specialty tests launched. Invitae integration completed.
FY26 guide of enterprise revenue +4.7-6% + adj EPS $17.65-$18.25 (+9% midpoint) + Diagnostics +5-6% + BLS +3-5% + FCF $1.24-$1.36B = continued multi-year compounding. Both segments expected to improve margins. Strategic investment in new central laboratory facility supports multi-year capacity + tech / AI rollout.
The risks are real — PAMA reimbursement cuts, competitive landscape (DGX + smaller), early development streamlining timing, Invitae integration tail, specialty test pricing, hospital + health system partnerships, FX, capital deployment + central lab investment, AI commoditization, reimbursement policy / Medicare Advantage, test mix shift / consumer DTC, macro utilization, goodwill / intangibles.
But the structural thesis (one of two largest US clinical lab diagnostics + global biopharma services + 130-test specialty cadence + Invitae integration + AI integration + Consumer Health DTC + new central lab + capital return discipline) is intact and FY25 print confirms.
Quality clinical laboratory diagnostics + biopharma services compounder mid-strategic-investment cycle. The Diagnostics +5-6% organic + BLS recovery + specialty mix expansion + AI integration creates a multi-year compounding setup. The FY26 +9% adj EPS growth on +5% revenue reflects operating leverage + margin expansion. Investors get exposure to clinical lab industry growth + specialty testing premium + biopharma drug development services + structural margin expansion.
Citations
- Labcorp Holdings Inc. FY25 Form 10-K (filed February 2026, SEC EDGAR).
- LH Q4 2025 earnings call, 2026-02-17 — Q4 Diagnostics revenue $2.7B (+5.5%) — organic +4.1%, acquisitions +1.5%; volume +2.2% / price-mix +3.3%; Q4 BLS revenue $793M (+3.4%) — organic +0.6%, FX +2.8%; Central Labs Q4 +11% (+8% cc); 130+ new specialty tests launched; Invitae integration completed; Labcorp OnDemand growing; new central laboratory facility investment; FY26 guide (enterprise revenue +4.7-6%; Diagnostics +5-6%; BLS +3-5%; adj EPS $17.65-$18.25 (+9% midpoint); FCF $1.24-$1.36B).
- LH Q3 2025 / Q2 2025 / Q1 2025 earnings calls — supporting Diagnostics + BLS dynamics + specialty test launches + Invitae integration (assumed in line with Q4 trajectory).
- Internal financial_statements view (consolidated annual + cash flow + capital structure).